ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

Abstract Vaccines against SARS-CoV-2 are urgently required, but early development of vaccines SARS-CoV-1 resulted in enhanced disease after vaccination. Careful assessment this phenomena is warranted for vaccine SARS CoV-2. Here we report detailed immune profiling ChAdOx1 nCoV-19 (AZD1222) and subsequent high dose challenge two animal models mediated disease. We demonstrate rhesus macaques the lung pathology caused by pneumonia reduced prior vaccination with which induced neutralising antibody responses a single intramuscular administration. In second model, ferrets, both virus shedding pathology. Antibody titre were boosted dose. Data from these on absence profiling, support continued clinical evaluation nCoV-19.